Lexicon Pharmaceuticals Balance Sheet Health
Financial Health criteria checks 5/6
Lexicon Pharmaceuticals has a total shareholder equity of $178.5M and total debt of $99.9M, which brings its debt-to-equity ratio to 56%. Its total assets and total liabilities are $321.1M and $142.6M respectively.
Key information
56.0%
Debt to equity ratio
US$99.90m
Debt
Interest coverage ratio | n/a |
Cash | US$258.37m |
Equity | US$178.51m |
Total liabilities | US$142.61m |
Total assets | US$321.12m |
Recent financial health updates
Here's Why Lexicon Pharmaceuticals (NASDAQ:LXRX) Can Manage Its Debt Despite Losing Money
Aug 08Here's Why Lexicon Pharmaceuticals (NASDAQ:LXRX) Can Manage Its Debt Despite Losing Money
Aug 08Recent updates
Lexicon Faces Uphill Battle As Inpefa Launch Disappoints, Eyes Type 1 Diabetes
Oct 16Here's Why Lexicon Pharmaceuticals (NASDAQ:LXRX) Can Manage Its Debt Despite Losing Money
Aug 08Lexicon Pharmaceuticals Needs To See Real Revenue Acceleration And Clinical/Regulatory Success
Aug 03Lexicon Pharmaceuticals: Blue Sky Aplenty, Revenue Not So Much
May 28Lexicon Pharmaceuticals: Moving To Maximize The Value Of Its Core Asset
Mar 12Lexicon Pharmaceuticals Putting The Pieces Together, But Much Is Left To Do
Jan 26Here's Why Lexicon Pharmaceuticals (NASDAQ:LXRX) Can Manage Its Debt Despite Losing Money
Aug 08Financial Position Analysis
Short Term Liabilities: LXRX's short term assets ($268.6M) exceed its short term liabilities ($36.0M).
Long Term Liabilities: LXRX's short term assets ($268.6M) exceed its long term liabilities ($106.6M).
Debt to Equity History and Analysis
Debt Level: LXRX has more cash than its total debt.
Reducing Debt: LXRX's debt to equity ratio has reduced from 148.8% to 56% over the past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: LXRX has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: LXRX has less than a year of cash runway if free cash flow continues to reduce at historical rates of 26% each year